Comparison of Sertraline and Escitalopram for Depression and Anxiety

Efficacy and Mechanism

Both medications work by blocking serotonin reuptake, but escitalopram's unique allosteric properties provide theoretical mechanistic advantages, as noted by the American Academy of Child and Adolescent Psychiatry 1

Both medications share common SSRI side effects including nausea, dry mouth, diarrhea, headache, somnolence, insomnia, sexual dysfunction, and behavioral activation/agitation, according to the Journal of the American Academy of Child and Adolescent Psychiatry 1
Sertraline carries moderate risk for discontinuation syndrome characterized by dizziness, fatigue, nausea, insomnia, and sensory disturbances following missed doses or acute discontinuation, as reported by the Journal of the American Academy of Child and Adolescent Psychiatry 2

Escitalopram has the lowest propensity for drug-drug interactions among SSRIs due to minimal effects on CYP450 isoenzymes, as stated by the Journal of the American Academy of Child and Adolescent Psychiatry and the American Academy of Child and Adolescent Psychiatry 2
Sertraline has moderate drug interaction potential through inhibition of CYP2D6, affecting metabolism of drugs including certain antipsychotics, beta-blockers, and other medications, according to the Journal of the American Academy of Child and Adolescent Psychiatry 2

Sertraline may require twice-daily dosing at low doses in youth, while escitalopram maintains once-daily dosing, as noted by the Journal of the American Academy of Child and Adolescent Psychiatry 1
Both medications demonstrate logarithmic response models with clinically significant improvement by week 6 and maximal improvement by week 12 or later, according to the Journal of the American Academy of Child and Adolescent Psychiatry 1

Both medications carry boxed warnings for suicidal thinking and behavior through age 24 years, with pooled absolute rates of 1% for antidepressants vs 0.2% for placebo, as reported by the Journal of the American Academy of Child and Adolescent Psychiatry 1
Close monitoring is essential, especially in the first months of treatment and following dosage adjustments, as stated by the Journal of the American Academy of Child and Adolescent Psychiatry and the American Academy of Child and Adolescent Psychiatry 1

Both medications are generally well tolerated with mild and temporary adverse events, according to the Journal of the American Academy of Child and Adolescent Psychiatry 1

The American Academy of Family Physicians recommends that the choice between escitalopram and sertralina for patients with major depressive disorder should be based on the side effect profile, drug interactions, and specific patient characteristics 3, 4
There is no clinically significant difference in efficacy between escitalopram and sertralina for major depression, according to the Annals of Internal Medicine 5, 6, 7, 8
Both medications are more effective in severe depression than in mild to moderate depression, as stated by the American Academy of Family Physicians 4

The American Academy of Family Physicians notes that nausea and vomiting are common causes of discontinuation for both escitalopram and sertralina 3, 4

The American Academy of Family Physicians recommends escitalopram as a preferred agent for elderly patients due to its favorable safety profile and lower potential for drug interactions 3, 4
Both escitalopram and sertralina are considered preferred agents for elderly patients, while paroxetine and fluoxetine should be avoided, according to the American Academy of Family Physicians 3, 4

The American Academy of Family Physicians recommends that the first episode of major depression should be treated for at least 4 months 3, 4
Patients with recurrent depression may benefit from prolonged treatment, as stated by the American Academy of Family Physicians 3, 4
The Annals of Internal Medicine suggests that treatment should be modified if there is no adequate response within 6-8 weeks 9
The response rate and remission rate for second-generation antidepressants, including escitalopram and sertralina, are 62% and 46%, respectively, according to the Annals of Internal Medicine 5, 6, 7